ReviewFrontiers in nephrology2022

SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules.

Yajiao Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.